Huapai Biotechnology

Huapai Biotechnology (Group) Co., Ltd. is a group enterprise focused on the research and development, production, sales, and technical services of animal protection products, including veterinary biological vaccines, antibodies, diagnostic reagents, and veterinary drugs. The company's history is deeply intertwined with the entrepreneurial journey of its founder and chairman, Xie Jianyong. Born in 1966, Xie Jianyong began his venture in 1993 by establishing the Sichuan Essence Feed Additive Factory. Recognizing the potential in animal health, he founded Sichuan Essence Animal Pharmaceutical Co., Ltd. in 1997. A pivotal moment came in 2003 with the establishment of Chengdu Essence Biological Products Co., Ltd., which played a significant role in supplying avian influenza vaccines in China. The brand 'Huapai' was formally established, leading to the creation of Huapai Bio-engineering Group Co., Ltd. in 2017 and culminating in Huapai Biotechnology (Group) Co., Ltd. in 2023.

Headquartered in Chengdu, the company operates five veterinary biological product manufacturing bases and an animal drug production base. Its extensive infrastructure includes 22 veterinary biological product production lines and 19 animal drug production lines, featuring China's first GMP-certified nucleic acid vaccine production line. Huapai's product portfolio is comprehensive, with over 40 veterinary vaccine products and more than 270 animal drug products. The company is notably the only one in China's animal health sector that covers all five major compulsory immunization vaccines: foot-and-mouth disease, peste des petits ruminants, brucellosis, echinococcosis, and avian influenza. Its business model involves the direct sale of these products and providing technical support to a client base that includes large-scale breeding groups.

Huapai places a strong emphasis on research and development, investing 10-15% of its revenue annually into the Huapai Group Research Institute. This institute collaborates with numerous national research bodies and universities. A significant achievement is the development of a foot-and-mouth disease virus-like particle (VLPs) vaccine, a global first that has received a national first-class new veterinary drug certificate. In August 2024, the company completed its first round of financing with investors including Guosen Hongsheng's Chuan-Yu Guanghong Fund and Jinmu Capital.

Keywords: veterinary vaccines, animal health, biological products, diagnostic reagents, animal pharmaceuticals, livestock disease control, foot-and-mouth disease vaccine, avian influenza vaccine, animal antibodies, veterinary drug manufacturing, nucleic acid vaccines, animal disease prevention, zoonotic disease control, agricultural biotechnology, veterinary R&D, livestock health solutions, animal medicine, biopharmaceuticals, China animal health, veterinary biotech